CA3132916A1 - Anti-v.beta.17/anti-cd123 bispecific antibodies - Google Patents
Anti-v.beta.17/anti-cd123 bispecific antibodies Download PDFInfo
- Publication number
- CA3132916A1 CA3132916A1 CA3132916A CA3132916A CA3132916A1 CA 3132916 A1 CA3132916 A1 CA 3132916A1 CA 3132916 A CA3132916 A CA 3132916A CA 3132916 A CA3132916 A CA 3132916A CA 3132916 A1 CA3132916 A1 CA 3132916A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- binding fragment
- bispecific antibody
- seq
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims abstract description 49
- 230000027455 binding Effects 0.000 claims description 226
- 239000000427 antigen Substances 0.000 claims description 205
- 108091007433 antigens Proteins 0.000 claims description 205
- 102000036639 antigens Human genes 0.000 claims description 205
- 210000004027 cell Anatomy 0.000 claims description 184
- 239000012634 fragment Substances 0.000 claims description 156
- 206010028980 Neoplasm Diseases 0.000 claims description 88
- 201000011510 cancer Diseases 0.000 claims description 79
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 75
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 59
- 150000007523 nucleic acids Chemical class 0.000 claims description 41
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 29
- 239000013598 vector Substances 0.000 claims description 22
- 230000003013 cytotoxicity Effects 0.000 claims description 21
- 231100000135 cytotoxicity Toxicity 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 13
- 230000001419 dependent effect Effects 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract description 8
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 abstract description 8
- 102100024092 Aldo-keto reductase family 1 member C4 Human genes 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 231100000820 toxicity test Toxicity 0.000 abstract 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 44
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 230000002147 killing effect Effects 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 229920001184 polypeptide Chemical group 0.000 description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 230000009977 dual effect Effects 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 7
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000002784 cytotoxicity assay Methods 0.000 description 6
- 231100000263 cytotoxicity test Toxicity 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000000833 heterodimer Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 231100000491 EC50 Toxicity 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 101100205847 Mus musculus Srst gene Proteins 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000005734 heterodimerization reaction Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229960003151 mercaptamine Drugs 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 102000052088 human IL3RA Human genes 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 101001079285 Homo sapiens Immunoglobulin heavy joining 1 Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100028078 Immunoglobulin heavy joining 1 Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- -1 LysC Proteins 0.000 description 2
- 239000012515 MabSelect SuRe Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 230000005880 cancer cell killing Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000012411 cloning technique Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- SBPPWJIDARICBS-PGCXOGMSSA-N (5r,5ar,8ar,9r)-5-[[(4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-phenyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4OC(OC[C@H]4O3)C=3C=CC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 SBPPWJIDARICBS-PGCXOGMSSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 229940086568 Alpha mannosidase I inhibitor Drugs 0.000 description 1
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
- 101000588924 Anthopleura elegantissima Delta-actitoxin-Ael1a Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000000579 Epigen Human genes 0.000 description 1
- 108010016906 Epigen Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000864782 Homo sapiens Surfactant-associated protein 2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010052781 Interleukin-3 Receptor alpha Subunit Proteins 0.000 description 1
- 102000018883 Interleukin-3 Receptor alpha Subunit Human genes 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- YINZYTTZHLPWBO-UHFFFAOYSA-N Kifunensine Natural products COC1C(O)C(O)C(O)C2NC(=O)C(=O)N12 YINZYTTZHLPWBO-UHFFFAOYSA-N 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 241001436793 Meru Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 241000208474 Protea Species 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 101710110949 Protein S100-A12 Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100030059 Surfactant-associated protein 2 Human genes 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000000375 direct analysis in real time Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012063 dual-affinity re-targeting Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- OIURYJWYVIAOCW-VFUOTHLCSA-N kifunensine Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H]2NC(=O)C(=O)N12 OIURYJWYVIAOCW-VFUOTHLCSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011824 transgenic rat model Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108091052247 type I cytokine receptor family Proteins 0.000 description 1
- 102000042286 type I cytokine receptor family Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816464P | 2019-03-11 | 2019-03-11 | |
| US62/816,464 | 2019-03-11 | ||
| PCT/IB2020/000342 WO2020183245A2 (en) | 2019-03-11 | 2020-03-11 | ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3132916A1 true CA3132916A1 (en) | 2020-09-17 |
Family
ID=71670296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3132916A Pending CA3132916A1 (en) | 2019-03-11 | 2020-03-11 | Anti-v.beta.17/anti-cd123 bispecific antibodies |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12264197B2 (enExample) |
| EP (1) | EP3937977A2 (enExample) |
| JP (2) | JP7566766B2 (enExample) |
| KR (1) | KR20210138033A (enExample) |
| CN (2) | CN119954959A (enExample) |
| AU (1) | AU2020235475A1 (enExample) |
| BR (1) | BR112021017801A2 (enExample) |
| CA (1) | CA3132916A1 (enExample) |
| IL (1) | IL286147A (enExample) |
| MA (1) | MA55305A (enExample) |
| MX (1) | MX2021010857A (enExample) |
| WO (1) | WO2020183245A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119954959A (zh) | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| JP2023509708A (ja) | 2020-01-03 | 2023-03-09 | マレンゴ・セラピューティクス，インコーポレーテッド | 抗ｔｃｒ抗体分子およびその使用 |
| WO2022035722A1 (en) * | 2020-08-10 | 2022-02-17 | Janssen Biotech, Inc. | Materials and methods for producing bioengineered virus specific lymphocytes |
| US12448449B2 (en) | 2020-09-11 | 2025-10-21 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| UY39416A (es) * | 2020-09-11 | 2022-03-31 | Janssen Biotech Inc | Moléculas de direccionamiento inmunes multiespecíficas y usos de estas |
| KR20230084508A (ko) | 2020-09-11 | 2023-06-13 | 얀센 바이오테크 인코포레이티드 | 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물 |
| TWI815194B (zh) * | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN119390841A (zh) * | 2021-11-01 | 2025-02-07 | 詹森生物科技公司 | 用于调节β链介导的免疫的组合物和方法 |
| WO2023152633A1 (en) * | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes |
| CN121127496A (zh) * | 2023-02-09 | 2025-12-12 | 杨森生物技术公司 | 抗Vβ17/抗CD123双特异性抗体 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221352B1 (en) | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
| US6413516B1 (en) | 1989-03-21 | 2002-07-02 | The Immune Response Corporation | Peptides and methods against psoriasis |
| FR2681875A1 (fr) | 1991-09-26 | 1993-04-02 | Immunotech Sa | Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vb17 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
| US6084087A (en) | 1991-09-27 | 2000-07-04 | New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery | DNA encoding conserved T-cell receptor sequences |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| DE69830065T2 (de) | 1997-09-16 | 2006-01-19 | Egea Biosciences, LLC, San Diego | Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1594542B1 (en) | 2003-02-20 | 2010-06-30 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| AU2006239860B2 (en) | 2005-04-25 | 2012-01-19 | Amgen Fremont Inc. | Antibodies to myostatin |
| US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| CA2722600C (en) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| US20110097339A1 (en) | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| RS56599B1 (sr) | 2010-06-15 | 2018-02-28 | Genmab As | Konjugati humanog antitela sa lekom protiv tkivnog faktora |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| EP2773671B1 (en) | 2011-11-04 | 2021-09-15 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| JP6163502B2 (ja) * | 2012-03-02 | 2017-07-12 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法 |
| WO2014159531A1 (en) | 2013-03-14 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases |
| MX386422B (es) | 2013-12-20 | 2025-03-18 | Fred Hutchinson Cancer Center | Moléculas efectoras químericas etiquetadas y receptores de las mismas. |
| CN107109420A (zh) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| JO3568B1 (ar) * | 2014-09-05 | 2020-07-05 | Janssen Pharmaceutica Nv | عوامل ربط cd123 واستخداماتها |
| EP3215538A4 (en) | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| MX381139B (es) | 2015-04-16 | 2025-03-12 | Eisai R&D Man Co Ltd | Anticuerpo anti-notch4 humano. |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| GB201516272D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| EP3554515A4 (en) * | 2016-12-15 | 2020-08-26 | Duke University | B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS |
| US11370830B2 (en) | 2017-04-07 | 2022-06-28 | The Rockefeller University | Neutralizing antibodies that bind to the zika virus domain III envelope region |
| WO2018223002A1 (en) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd 123 cd3 |
| WO2019091384A1 (en) | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| MX2020014243A (es) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| AU2020204686A1 (en) | 2019-01-04 | 2021-07-22 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN119954959A (zh) | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| AU2020298324A1 (en) | 2019-06-21 | 2022-01-27 | Single Cell Technology, Inc. | Anti-TIGIT antibodies |
| BR112022006439A2 (pt) | 2019-10-03 | 2022-07-05 | Janssen Biotech Inc | Métodos para produção de bioterapêuticos com estabilidade aumentada por otimização de sequência |
| KR20220147631A (ko) | 2020-02-27 | 2022-11-03 | 얀센 바이오테크 인코포레이티드 | 면역 반응을 조절하기 위한 물질 및 방법 |
| UY39416A (es) | 2020-09-11 | 2022-03-31 | Janssen Biotech Inc | Moléculas de direccionamiento inmunes multiespecíficas y usos de estas |
| US12448449B2 (en) | 2020-09-11 | 2025-10-21 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| KR20230084508A (ko) | 2020-09-11 | 2023-06-13 | 얀센 바이오테크 인코포레이티드 | 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물 |
-
2020
- 2020-03-11 CN CN202510015884.6A patent/CN119954959A/zh active Pending
- 2020-03-11 JP JP2021553382A patent/JP7566766B2/ja active Active
- 2020-03-11 KR KR1020217031687A patent/KR20210138033A/ko active Pending
- 2020-03-11 BR BR112021017801A patent/BR112021017801A2/pt unknown
- 2020-03-11 MX MX2021010857A patent/MX2021010857A/es unknown
- 2020-03-11 US US17/437,771 patent/US12264197B2/en active Active
- 2020-03-11 CN CN202080034083.XA patent/CN113874400B/zh active Active
- 2020-03-11 MA MA055305A patent/MA55305A/fr unknown
- 2020-03-11 CA CA3132916A patent/CA3132916A1/en active Pending
- 2020-03-11 EP EP20742831.9A patent/EP3937977A2/en active Pending
- 2020-03-11 AU AU2020235475A patent/AU2020235475A1/en active Pending
- 2020-03-11 WO PCT/IB2020/000342 patent/WO2020183245A2/en not_active Ceased
-
2021
- 2021-09-05 IL IL286147A patent/IL286147A/en unknown
-
2024
- 2024-08-13 JP JP2024135000A patent/JP2024170426A/ja active Pending
-
2025
- 2025-02-24 US US19/061,801 patent/US20250257132A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119954959A (zh) | 2025-05-09 |
| WO2020183245A3 (en) | 2020-12-03 |
| MX2021010857A (es) | 2021-12-15 |
| AU2020235475A1 (en) | 2021-09-30 |
| JP2022523442A (ja) | 2022-04-22 |
| CN113874400B (zh) | 2025-02-07 |
| MA55305A (fr) | 2022-01-19 |
| CN113874400A (zh) | 2021-12-31 |
| IL286147A (en) | 2021-10-31 |
| KR20210138033A (ko) | 2021-11-18 |
| WO2020183245A2 (en) | 2020-09-17 |
| EP3937977A2 (en) | 2022-01-19 |
| JP7566766B2 (ja) | 2024-10-15 |
| JP2024170426A (ja) | 2024-12-10 |
| US12264197B2 (en) | 2025-04-01 |
| US20250257132A1 (en) | 2025-08-14 |
| US20220127359A1 (en) | 2022-04-28 |
| BR112021017801A2 (pt) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250257132A1 (en) | ANTI-Vbeta17/ANTI-CD123 BISPECIFIC ANTIBODIES | |
| JP7469432B2 (ja) | 抗ｇｐｒｃ５ｄ抗体、ｇｐｒｃ５ｄとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 | |
| US12460001B2 (en) | Proteins comprising CD3 antigen binding domains and uses thereof | |
| US11827708B2 (en) | Proteins comprising HLA-G antigen binding domains and their uses | |
| US20240150464A1 (en) | Materials and methods for modulating t cell mediated immunity | |
| KR20160029128A (ko) | 이중특이적 cd3 및 cd19 항원 결합 구조체 | |
| CN115298221A (zh) | 结合b7h4的抗体 | |
| US12448449B2 (en) | Immune targeting molecules and uses thereof | |
| EP4662239A1 (en) | Anti-v beta 17/anti-cd123 bispecific antibodies | |
| RU2831786C2 (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К Vβ17/CD123 | |
| CN118742566A (zh) | 包含用于免疫应答的增强型多特异性结合剂的组合物 | |
| HK40083338A (en) | Antibodies binding to b7h4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240304 |